GH Research PLC
NASDAQ:GHRSBiotechnology
-$0.04 today
- Market cap
- $1.25B
- Beta
- 1.31
- P/E (TTM)
- -23.8
- EPS (TTM)
- -$0.91
Volume 0.46M
Average 0.23M
GHRS Total Non-current Assets
All assets not expected to be converted to cash within one year.
GH Research PLCNASDAQ: GHRS
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets falls 88.2% from a year ago
Total non-current assets stood at $3.04M at the end of Q1 FY2026, down 88.2% from a year earlier and up 34.6% from the prior quarter. Over 3 fiscal years it compounded at -70.3% a year.
Context
- Total non-current assets amounted to 1.1% of total assets at the end of Q1 FY2026, down 6.9 pp from a year earlier.
- Total non-current assets increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current assets keeps falling in the next quarterly balance sheet after a -88.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 2.25M USD
- Year-over-year change
- -93.4%
- 4-year CAGR
- +129.0%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.25M | -93.4% |
| FY2024 | 2024-12-31 | 34.05M | -45.3% |
| FY2023 | 2023-12-31 | 62.21M | -27.5% |
| FY2022 | 2022-12-31 | 85.82M | +104559.8% |
| FY2021 | 2021-12-31 | 82K | — |
Total Non-current Assets vs competitors
How GHRS compares with its peers on the latest reported figures
- GHRS's Mar 2026 total non-current assets of $3.04M is the 8th highest of the 9 companies compared; the peer median is $17.71M.
- Its year-over-year change of -88.2% is the lowest of 9, against a peer median of +2.8%.
- Total non-current assets amounts to 1.1% of total assets for GHRS, versus a peer median of 2.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $15.36B | +103156.5% | -0.1% | 16.1% | |
| Mar 2026 | $91.56M | +588.3% | +176.1% | 21.9% | |
| Jun 2026 | $74.18M | -1.9% | +3.6% | 20.0% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $22.52M | +6.9% | -4.6% | 2.1% |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $12.9M | +16.4% | +245.9% | 2.6% |
| Mar 2026 | $7.13M | -15.0% | +62.2% | 2.6% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $4.41M | -1.3% | +1044.9% | 1.1% |
| Mar 2026 | $3.04M | -88.2% | -70.3% | 1.1% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $443K | -76.5% | -76.3% | 0.3% |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding GHRS) | $17.71M | +2.8% | +32.9% | 2.6% | |
Competitors are the stored peer set for GHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 276.78M | 165.96M | 78.42M | 100.79M | 246.25M |
| Short-term Investments | 0 | 0 | 83.14M | 48.53M | 34.46M |
| Net Receivables | 48K | 90K | 178K | 1.73M | 1.3M |
| Inventory | 3.01M | (90K) | 0 | 0 | 0 |
| Other Current Assets | 10K | 47K | 119K | 0 | 0 |
| Total Current Assets | 279.84M | 168.54M | 164.09M | 154.23M | 285.98M |
| Property, Plant & Equipment (Net) | 82K | 97K | 1.07M | 748K | 620K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 85.72M | 61.14M | 33.3M | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 1.63M |
| Total Non-current Assets | 82K | 85.82M | 62.21M | 34.05M | 2.25M |
| Total Assets | 279.92M | 254.36M | 226.3M | 188.27M | 288.23M |
| Account Payables | 883K | 1.87M | 3.49M | 3.74M | 3.77M |
| Short-term Debt | 0 | 0 | 343K | 255K | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 168K | 312K | 6.36M | 8.7M | 407K |
| Total Current Liabilities | 2.75M | 4.55M | 6.7M | 8.95M | 8.38M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 1.87M | 631K | 369K | 147K |
| Total Liabilities | 2.75M | 4.55M | 7.33M | 9.32M | 8.53M |
| Common Stock | 1.3M | 1.3M | 1.3M | 1.3M | 1.55M |
| Retained Earnings | (10.04M) | (32.49M) | (67.94M) | (106.45M) | (154.43M) |
| Accumulated OCI | (5.54M) | (10.44M) | (5.86M) | (7.37M) | 1.52M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 277.18M | 249.82M | 218.97M | 178.95M | 279.7M |
| Total Debt | 0 | 0 | 974K | 624K | 512K |
| Net Debt | (276.78M) | (165.96M) | (77.45M) | (100.17M) | (245.74M) |
GH Research PLC
NASDAQ:GHRS
Intrinsic Alpha fair value
Locked
Current Price
$18.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.